NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.
The test, which runs on the Swiss company's high-throughput MosaiQ System, detects 15 different autoantibodies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback